Sherbrooke Park Advisers’s MaxCyte MXCT Stock Holding History

Sherbrooke Park Advisers’s Portfolio MXCT Stock Details MXCT Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2024 Q4	–	Sell	-35,287	Closed	-$137K	–	1027
2024 Q3	$137K	Buy	+35,287	New	+$149K	0.03%	809
2024 Q2	–	Sell	-42,895	Closed	-$180K	–	1110
2024 Q1	$180K	Buy	42,895 +10,517	+32%	+$49.4K	0.04%	743
2023 Q4	$152K	Buy	+32,378	New	+$126K	0.07%	361

Other funds holding MXCT

CCM

Cadian Capital Management New York $821M AUM 14.36% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Vitruvian Partners London, United Kingdom $112M AUM 2.02% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

MFS

Mirabella Financial Services London, United Kingdom $1.06B AUM 19.83% 1-Year Est. Return

RGI

River Global Investors London, United Kingdom $515M AUM 24.86% 1-Year Est. Return

Mudita Advisors London, United Kingdom $490M AUM 66.64% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

Sherbrooke Park Advisers's MXCT Position: Q4 2024 in Review

Sherbrooke Park Advisers sold out of MaxCyte (MXCT) in Q4 2024, closing a stake of 35,287 shares — an estimated $137K sold.

Sherbrooke Park Advisers first reported a position in MXCT in Q4 2023 and held it in 3 quarters. The position peaked at $180K in Q1 2024. 119 funds tracked by Wall St. Rank hold MXCT as of Q4 2024.

Sherbrooke Park Advisers reported no remaining MaxCyte position as of Q4 2024 after selling out during the quarter.
Sherbrooke Park Advisers sold 35,287 MaxCyte shares in Q4 2024, an estimated $137K.
Sherbrooke Park Advisers first reported a position in MaxCyte in Q4 2023 and held it in 3 quarters.
Sherbrooke Park Advisers's MaxCyte position peaked at $180K in Q1 2024.
119 funds tracked by Wall St. Rank held MaxCyte as of Q4 2024.

Based on Sherbrooke Park Advisers's 13F filing for Q4 2024, filed 14 Feb 2025.